Casey M Rebholz1,2, Bing Yu3, Zihe Zheng4,5, Patrick Chang3, Adrienne Tin4,5, Anna Köttgen4,6, Lynne E Wagenknecht7, Josef Coresh4,5, Eric Boerwinkle3, Elizabeth Selvin4,5. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD, 21205, USA. crebhol1@jhu.edu. 2. Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. crebhol1@jhu.edu. 3. Department of Epidemiology, Human Genetics & Environmental Sciences, University of Texas Health Sciences Center at Houston School of Public Health, Houston, TX, USA. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD, 21205, USA. 5. Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 6. Institute of Genetic Epidemiology, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany. 7. Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Abstract
AIMS/HYPOTHESIS: Metabolomic profiling offers the potential to reveal metabolic pathways relevant to the pathophysiology of diabetes and improve diabetes risk prediction. METHODS: We prospectively analysed known metabolites using an untargeted approach in serum specimens from baseline (1987-1989) and incident diabetes through to 31 December 2015 in a subset of 2939 Atherosclerosis Risk in Communities (ARIC) study participants with metabolomics data and without prevalent diabetes. RESULTS: Among the 245 named compounds identified, seven metabolites were significantly associated with incident diabetes after Bonferroni correction and covariate adjustment; these included a food additive (erythritol) and compounds involved in amino acid metabolism [isoleucine, leucine, valine, asparagine, 3-(4-hydoxyphenyl)lactate] and glucose metabolism (trehalose). Higher levels of metabolites were associated with increased risk of incident diabetes (HR per 1 SD increase in isoleucine 2.96, 95% CI 2.02, 4.35, p = 3.18 × 10-8; HR per 1 SD increase in trehalose 1.16, 95% CI 1.09, 1.25, p = 1.87 × 10-5), with the exception of asparagine, which was associated with a lower risk of diabetes (HR per 1 SD increase in asparagine 0.78, 95% CI 0.71, 0.85, p = 4.19 × 10-8). The seven metabolites modestly improved prediction of incident diabetes beyond fasting glucose and established risk factors (C statistics 0.744 vs 0.735, p = 0.001 for the difference in C statistics). CONCLUSIONS/ INTERPRETATION: Branched chain amino acids may play a role in diabetes development. Our study is the first to report asparagine as a protective biomarker of diabetes risk. The serum metabolome reflects known and novel metabolic disturbances that improve prediction of diabetes.
AIMS/HYPOTHESIS: Metabolomic profiling offers the potential to reveal metabolic pathways relevant to the pathophysiology of diabetes and improve diabetes risk prediction. METHODS: We prospectively analysed known metabolites using an untargeted approach in serum specimens from baseline (1987-1989) and incident diabetes through to 31 December 2015 in a subset of 2939 Atherosclerosis Risk in Communities (ARIC) study participants with metabolomics data and without prevalent diabetes. RESULTS: Among the 245 named compounds identified, seven metabolites were significantly associated with incident diabetes after Bonferroni correction and covariate adjustment; these included a food additive (erythritol) and compounds involved in amino acid metabolism [isoleucine, leucine, valine, asparagine, 3-(4-hydoxyphenyl)lactate] and glucose metabolism (trehalose). Higher levels of metabolites were associated with increased risk of incident diabetes (HR per 1 SD increase in isoleucine 2.96, 95% CI 2.02, 4.35, p = 3.18 × 10-8; HR per 1 SD increase in trehalose 1.16, 95% CI 1.09, 1.25, p = 1.87 × 10-5), with the exception of asparagine, which was associated with a lower risk of diabetes (HR per 1 SD increase in asparagine 0.78, 95% CI 0.71, 0.85, p = 4.19 × 10-8). The seven metabolites modestly improved prediction of incident diabetes beyond fasting glucose and established risk factors (C statistics 0.744 vs 0.735, p = 0.001 for the difference in C statistics). CONCLUSIONS/ INTERPRETATION:Branched chain amino acids may play a role in diabetes development. Our study is the first to report asparagine as a protective biomarker of diabetes risk. The serum metabolome reflects known and novel metabolic disturbances that improve prediction of diabetes.
Authors: Elizabeth Selvin; Michael W Steffes; Hong Zhu; Kunihiro Matsushita; Lynne Wagenknecht; James Pankow; Josef Coresh; Frederick L Brancati Journal: N Engl J Med Date: 2010-03-04 Impact factor: 91.245
Authors: Alena Stancáková; Mete Civelek; Niyas K Saleem; Pasi Soininen; Antti J Kangas; Henna Cederberg; Jussi Paananen; Jussi Pihlajamäki; Lori L Bonnycastle; Mario A Morken; Michael Boehnke; Päivi Pajukanta; Aldons J Lusis; Francis S Collins; Johanna Kuusisto; Mika Ala-Korpela; Markku Laakso Journal: Diabetes Date: 2012-05-02 Impact factor: 9.461
Authors: Ele Ferrannini; Andrea Natali; Stefania Camastra; Monica Nannipieri; Andrea Mari; Klaus-Peter Adam; Michael V Milburn; Gabi Kastenmüller; Jerzy Adamski; Tiinamaija Tuomi; Valeriya Lyssenko; Leif Groop; Walter E Gall Journal: Diabetes Date: 2012-11-16 Impact factor: 9.461
Authors: Jinying Zhao; Yun Zhu; Noorie Hyun; Donglin Zeng; Karan Uppal; ViLinh T Tran; Tianwei Yu; Dean Jones; Jiang He; Elisa T Lee; Barbara V Howard Journal: Diabetes Care Date: 2014-12-02 Impact factor: 19.112
Authors: Lisa Schlicker; Doletha M E Szebenyi; Semira R Ortiz; Alexander Heinz; Karsten Hiller; Martha S Field Journal: J Biol Chem Date: 2019-09-11 Impact factor: 5.157
Authors: S L Andersen; F B S Briggs; J H Winnike; Y Natanzon; S Maichle; K J Knagge; L K Newby; S G Gregory Journal: Mult Scler Relat Disord Date: 2019-03-09 Impact factor: 4.339
Authors: Kevin R Short; Jennifer Q Chadwick; April M Teague; Mary A Tullier; Lisa Wolbert; Charlotte Coleman; Kenneth C Copeland Journal: J Clin Endocrinol Metab Date: 2019-08-01 Impact factor: 5.958
Authors: Danielle E Haslam; Liming Liang; Dong D Wang; Rachel S Kelly; Clemens Wittenbecher; Cynthia M Pérez; Marijulie Martínez; Chih-Hao Lee; Clary B Clish; David T W Wong; Laurence D Parnell; Chao-Qiang Lai; José M Ordovás; JoAnn E Manson; Frank B Hu; Meir J Stampfer; Katherine L Tucker; Kaumudi J Joshipura; Shilpa N Bhupathiraju Journal: BMJ Open Diabetes Res Care Date: 2021-08
Authors: Yiming Zhang; Nurmohammad Shaikh; Jeremie L Ferey; Umesh D Wankhade; Sree V Chintapalli; Cassandra B Higgins; Jan R Crowley; Monique R Heitmeier; Alicyn I Stothard; Belgacem Mihi; Misty Good; Takanobu Higashiyama; Benjamin M Swarts; Paul W Hruz; Kartik Shankar; Phillip I Tarr; Brian J DeBosch Journal: Gastroenterology Date: 2019-12-12 Impact factor: 22.682
Authors: Alvaro Alonso; Bing Yu; Yan V Sun; Lin Y Chen; Laura R Loehr; Wesley T O'Neal; Elsayed Z Soliman; Eric Boerwinkle Journal: Am J Cardiol Date: 2019-03-18 Impact factor: 2.778
Authors: Zsu-Zsu Chen; Jinxi Liu; Jordan Morningstar; Brandy M Heckman-Stoddard; Christine G Lee; Samuel Dagogo-Jack; Jane F Ferguson; Richard F Hamman; William C Knowler; Kieren J Mather; Leigh Perreault; Jose C Florez; Thomas J Wang; Clary Clish; Marinella Temprosa; Robert E Gerszten Journal: Diabetes Date: 2019-10-03 Impact factor: 9.461
Authors: Qibin Qi; Jun Li; Bing Yu; Jee-Young Moon; Jin C Chai; Jordi Merino; Jie Hu; Miguel Ruiz-Canela; Casey Rebholz; Zheng Wang; Mykhaylo Usyk; Guo-Chong Chen; Bianca C Porneala; Wenshuang Wang; Ngoc Quynh Nguyen; Elena V Feofanova; Megan L Grove; Thomas J Wang; Robert E Gerszten; Josée Dupuis; Jordi Salas-Salvadó; Wei Bao; David L Perkins; Martha L Daviglus; Bharat Thyagarajan; Jianwen Cai; Tao Wang; JoAnn E Manson; Miguel A Martínez-González; Elizabeth Selvin; Kathryn M Rexrode; Clary B Clish; Frank B Hu; James B Meigs; Rob Knight; Robert D Burk; Eric Boerwinkle; Robert C Kaplan Journal: Gut Date: 2021-06-14 Impact factor: 31.793